Real-Time Continuous Glucose Monitors

Real-Time Continuous Glucose Monitors

A continuous glucose monitor (CGM) is a small wearable glucose monitoring device that continuously measures and tracks a person's glucose levels for the management of diabetes. A CGM is designed to supplement finger stick blood glucose testing for diabetes treatment decisions. A CGM may aid in the detection of episodes of hyperglycemia and hypoglycemia by using alarms and/or alerts to inform patients when blood glucose levels are exceeding or falling below specified thresholds.

The New York State Department of Health will make a determination whether or not to add coverage of this technology to the Medicaid benefit package.

Dossier sources of evidence already submitted:

The following evidence was recently submitted to the Department:

- 1. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795-800.
- 2. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155-3162.
- 3. Battelino T, Liabat S, Veeze HJ, et al. Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus. Diabet Med. 2015;32:1568-1574.
- 4. Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucose monitoring in wellcontrolled type 1 diabetes. Diabetes Care. 2009;32:1378-1383.
- 5. Bode B, Beck RW, Xing D, et al. Sustained benefit of continuous glucose monitoring on HbA1c, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32:2047-2049.
- 6. Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring J Diabetes Sci Technol. 2016.
- 7. Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation

continuous glucose monitoring randomized trial. Diabetes Technol Ther. 2010;12:507-515.

- 8. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29:2730-2732.
- 9. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10:377-383.
- 10. Huang ES, O'Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33:1269-1274.
- 11. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33:17-22.
- 12. Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53:2487-2495.
- 13. Mauras N, Beck R, Xing D, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care. 2012;35:204-210.
- 14. McQueen RB, Ellis SL, Campbell JD, et al. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011;9:13.
- 15. New JP, Ajjan R, Pfeiffer AF, et al. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med. 2015;32:609-617.
- 16. O'Connell MA, Donath S, O'Neal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52:1250-1257.
- 17. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The RealTrend study. Diabetes Care. 2009;32:2245-2250.

- 18. Radermecker RP, Saint Remy A, Scheen AJ, et al. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes Metab. 2010;36:409-413.
- 19. Riveline JP, Schaepelynck P, Chaillous L, et al. Assessment of patient-led or physiciandriven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care. 2012;35:965-971.
- 20. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
- 21. Tildesley HD, Wright AM, Chan JH, et al. A comparison of internet monitoring with continuous glucose monitoring in insulin-requiring type 2 diabetes mellitus. Can J Diabetes. 2013;37:305-308.
- 22. Wojciechowski P, Rys P, Lipowska A, et al. Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis. Pol Arch Med Wewn. 2011;121:333-343.
- 23. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336-47.